BACKGROUND: Primary plasma cell leukemia (PCL) is a rare plasma cell disorder, and current knowledge regarding survival in this disease is limited to small series of patients. Although there has been significant improvement in the survival of patients with multiple myeloma (MM) over the past few decades, it is not known whether there has been a similar trend for PCL. METHODS: The authors analyzed the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the characteristics and survival of patients who had PCL compared with those of patients who had MM. RESULTS: Among 291 patients with PCL, the median age was 67 years (range, 19-98 years), the distribution of men and women was nearly equal, and the majority of patients were white (79.4%). The median overall survival (OS) was 4 months and the median disease-specific survival (DSS) was 6 months for patients with PCL; the 1-year, 2-year, and 5-year OS rates were 27.8%, 14.1%, and 6.4%, respectively. There were no survival differences noted according to sex or race. Patients aged<60 years were found to have a better median OS compared with patients aged>or=60 years (median OS, 7 months vs 3 months; P=.007), although the 5-year OS was equally poor in both groups (6.3% vs 6.4%, respectively). During the same period, 49,106 patients with MM were identified. Unlike MM, in which there has been a modest but statistically significant improvement in OS and DSS noted over time, no significant improvement was evident for PCL. CONCLUSIONS: The poor long-term outcome and the lack of survival improvement in PCL suggest the need for better therapeutic options for these patients. Copyright (c) 2009 American Cancer Society.
BACKGROUND: Primary plasma cell leukemia (PCL) is a rare plasma cell disorder, and current knowledge regarding survival in this disease is limited to small series of patients. Although there has been significant improvement in the survival of patients with multiple myeloma (MM) over the past few decades, it is not known whether there has been a similar trend for PCL. METHODS: The authors analyzed the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the characteristics and survival of patients who had PCL compared with those of patients who had MM. RESULTS: Among 291 patients with PCL, the median age was 67 years (range, 19-98 years), the distribution of men and women was nearly equal, and the majority of patients were white (79.4%). The median overall survival (OS) was 4 months and the median disease-specific survival (DSS) was 6 months for patients with PCL; the 1-year, 2-year, and 5-year OS rates were 27.8%, 14.1%, and 6.4%, respectively. There were no survival differences noted according to sex or race. Patients aged<60 years were found to have a better median OS compared with patients aged>or=60 years (median OS, 7 months vs 3 months; P=.007), although the 5-year OS was equally poor in both groups (6.3% vs 6.4%, respectively). During the same period, 49,106 patients with MM were identified. Unlike MM, in which there has been a modest but statistically significant improvement in OS and DSS noted over time, no significant improvement was evident for PCL. CONCLUSIONS: The poor long-term outcome and the lack of survival improvement in PCL suggest the need for better therapeutic options for these patients. Copyright (c) 2009 American Cancer Society.
Authors: Wilson I Gonsalves; S Vincent Rajkumar; Ronald S Go; Angela Dispenzieri; Vinay Gupta; Preet P Singh; Francis K Buadi; Martha Q Lacy; Prashant Kapoor; David Dingli; John A Lust; Steven R Zeldenrust; Suzanne R Hayman; Robert A Kyle; Morie A Gertz; Shaji K Kumar Journal: Blood Date: 2014-06-23 Impact factor: 22.113
Authors: Mubarak Ariyo Bidmos; Sunette Joubert; Magdalena F P C van Jaarsveld; Vernon J Louw Journal: Int J Hematol Date: 2013-11-21 Impact factor: 2.490
Authors: C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah Journal: Leukemia Date: 2012-11-21 Impact factor: 11.528
Authors: A Mahindra; M E Kalaycio; J Vela-Ojeda; D H Vesole; M-J Zhang; P Li; J R Berenson; J M Bird; A Dispenzieri; J L Gajewski; R P Gale; L Holmberg; S Kumar; R A Kyle; H M Lazarus; S Lonial; J Mikhael; G A Milone; R Munker; R Nath; S Saccaro; L Bik To; D T Vogl; B Wirk; P Hari Journal: Leukemia Date: 2011-11-01 Impact factor: 11.528
Authors: Bharat Nandakumar; Shaji K Kumar; Angela Dispenzieri; Francis K Buadi; David Dingli; Martha Q Lacy; Suzanne R Hayman; Prashant Kapoor; Nelson Leung; Amie Fonder; Miriam Hobbs; Yi Lisa Hwa; Eli Muchtar; Rahma Warsame; Taxiarchis V Kourelis; Stephen Russell; John A Lust; Yi Lin; Mustaqeem Siddiqui; Ronald S Go; Dragan Jevremovic; Robert A Kyle; Morie A Gertz; S Vincent Rajkumar; Wilson I Gonsalves Journal: Mayo Clin Proc Date: 2021-03 Impact factor: 7.616